Nightingale Health
2.1 EUR +2.44%Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.
Latest research
Extensive report
Analyst
![Antti Luiro Antti Luiro](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://core.inderes.fi/sites/default/files/2023-08/Antti_Luiro.jpg)
Latest videos
Financial calendar
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Cor Group Oy | 10.2 % | 12.7 % |
Antti Kangas | 8.8 % | 21.8 % |
Premium
This content is for our Premium customers only.
Insider Transactions
Insider | Date | Total value |
---|---|---|
Olli Karhi | 03.07.2024 | 1,073,684EUR |
Ilkka Laurila | 12.10.2023 | 8,831EUR |
Premium
This content is for our Premium customers only.
Forum updates
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 1.8 | 2.3 | 2.3 | 4.2 | 4.7 | 8.7 | 15.1 | 24.9 |
growth-% | -13.0 % | 29.4 % | 0.3 % | 80.8 % | 12.8 % | 85.0 % | 72.7 % | 65.0 % |
EBITDA | -3.1 | -7.3 | -9.4 | -12.9 | -9.8 | -9.6 | -6.4 | -0.7 |
EBIT (adj.) | -3.3 | -8.6 | -13.6 | -18.5 | -17.8 | -17.6 | -13.1 | -6.7 |
EBIT | -3.3 | -9.8 | -13.6 | -18.5 | -17.8 | -17.6 | -13.1 | -6.7 |
Profit before taxes | -3.7 | -9.7 | -16.2 | -18.2 | -16.3 | -16.7 | -12.4 | -6.3 |
Net income | -3.7 | -9.7 | -16.1 | -18.2 | -16.4 | -16.7 | -11.8 | -5.9 |
EPS (adj.) | -0.21 | -0.23 | -0.30 | -0.27 | -0.27 | -0.19 | -0.10 | |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Login required
This content is only available for logged in users
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -174.9 % | -316.7 % | -405.9 % | -308.4 % | -208.5 % | -110.2 % | -42.6 % | -2.8 % |
EBIT-% (adj.) | -187.6 % | -375.0 % | -589.5 % | -442.9 % | -377.5 % | -201.9 % | -87.0 % | -26.9 % |
EBIT-% | -187.6 % | -423.2 % | -589.5 % | -442.9 % | -377.5 % | -201.9 % | -87.0 % | -26.9 % |
ROE | -62.3 % | -15.0 % | -13.7 % | -17.4 % | -18.4 % | -23.0 % | -20.3 % | -12.0 % |
ROI | -26.1 % | -13.7 % | -11.1 % | -17.1 % | -19.4 % | -23.1 % | -20.8 % | -12.3 % |
Login required
This content is only available for logged in users
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 3.68 | 1.02 | 1.12 | 2.10 | 2.10 | 2.10 | 2.10 | |
Shares | 60.5 | 60.9 | 60.9 | 60.9 | 60.9 | 60.9 | 60.9 | |
Market cap | 222.5 | 61.9 | 68.0 | 127.9 | 127.9 | 127.9 | 127.9 | |
Enterprise value | 114.6 | -28.9 | -10.0 | 62.1 | 75.7 | 88.4 | 94.5 | |
EV/S | - | 49.7 | - | - | 13.2 | 8.7 | 5.9 | 3.8 |
EV/EBITDA | - | - | 3.1 | 0.8 | - | - | - | - |
EV/EBIT (adj.) | - | - | 2.1 | 0.5 | - | - | - | - |
EV/EBIT | - | - | 2.1 | 0.5 | - | - | - | - |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | - | 1.8 | 0.6 | 0.7 | 1.6 | 2.0 | 2.4 | 2.7 |
P/S | - | 96.5 | 26.8 | 16.3 | 27.1 | 14.7 | 8.5 | 5.1 |
Dividend yield | ||||||||
Equity ratio | 23.2 % | 88.5 % | 89.8 % | 91.2 % | 88.7 % | 84.0 % | 78.6 % | 71.7 % |
Gearing ratio | 87.6 % | -87.4 % | -81.3 % | -80.1 % | -81.3 % | -81.2 % | -75.4 % | -71.8 % |
Login required
This content is only available for logged in users
Quarter data
Q3/23 | Q4/23 | 2023 | Q1/24 | Q2/24 | Q3/24e | Q4/24e | 2024e | Q1/25e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 1.9 | 4.2 | 1.7 | 3.0 | 4.7 | ||||
EBITDA | -7.4 | -12.9 | -5.3 | -4.5 | -9.8 | ||||
EBIT | -9.9 | -18.5 | -9.3 | -8.5 | -17.8 | ||||
Profit before taxes | -9.7 | -18.2 | -8.5 | -7.8 | -16.3 | ||||
Net income | -9.7 | -18.2 | -8.5 | -7.8 | -16.4 |
Login required
This content is only available for logged in users
Summary of Financial Year 7/2023 - 6/2024: Nightingale Health achieved several breakthroughs in adopting the company's technology in healthcare
Nightingale starts a new strategic partnership with 23andMe and launches a pilot
Join Inderes community
Don't miss out - create an account and get all the possible benefits